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Glycosylation is a topic of intense current interest in the
development of biopharmaceuticals because it is related
to drug safety and efficacy. This work describes results of
an interlaboratory study on the glycosylation of the Pri-
mary Sample (PS) of NISTmAb, a monoclonal antibody
reference material. Seventy-six laboratories from indus-
try, university, research, government, and hospital sec-
tors in Europe, North America, Asia, and Australia submit-
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ted a total of 103 reports on glycan distributions. The
principal objective of this study was to report and com-
pare results for the full range of analytical methods pres-
ently used in the glycosylation analysis of mAbs. There-
fore, participation was unrestricted, with laboratories
choosing their own measurement techniques. Protein gly-
cosylation was determined in various ways, including at
the level of intact mAb, protein fragments, glycopeptides,
or released glycans, using a wide variety of methods for
derivatization, separation, identification, and quantifica-
tion. Consequently, the diversity of results was enormous,
with the number of glycan compositions identified by
each laboratory ranging from 4 to 48. In total, one hundred
sixteen glycan compositions were reported, of which 57
compositions could be assigned consensus abundance
values. These consensus medians provide community-
derived values for NISTmAb PS. Agreement with the con-
sensus medians did not depend on the specific method or
laboratory type. The study provides a view of the current
state-of-the-art for biologic glycosylation measurement
and suggests a clear need for harmonization of glycosy-
lation analysis methods. Molecular & Cellular Proteom-
ics 19: 11–30, 2020. DOI: 10.1074/mcp.RA119.001677.
Biologics have recently emerged as critically important drugs
from health and economic perspectives. Two-thirds of ap-
proved biologics are glycoproteins, i.e. proteins containing gly-
cans as post-translational modification. Alteration in glycosyla-
tion may impact the safety and efficacy of the drug, including its
clearance rates, effector functions, folding, immunogenicity,
solubility, and biological activity. In addition to glycomic profiling
of new drug candidates, analysis of glycoforms is essential for
monitoring production batches of established drugs and com-
paring biosimilars and biobetters to originator drugs.
This report describes results of a broad interlaboratory
study designed to determine both the level of variability in
current measurement methods as well as to support consen-
sus measurement values for a reference material. Participa-
tion was open to all laboratories, regardless of experience or
preferred analytical method. Because specific methods se-
lected by participating laboratories varied greatly, as did their
degree of expertise, this study was not designed to determine
“best” methods, but to provide a “snapshot” of the currently
used methods for biologic glycosylation measurement. Unfor-
tunately, this diversity in experience and objective prevented
a deeper analysis of the variability of results, with some highly
experienced labs using well-developed standard operating
procedures, and with others using novel approaches or ex-
ploiting their unique capabilities. The study rationale and de-
sign are presented in detail in supplementary Discussion S1.
Glycosylation analysis is inherently challenging because,
unlike amino acids in proteins which are encoded by the
genome, sequential addition of monosaccharide residues is
not template-driven. It is rather dictated by competing enzy-
matic activities, leading to heterogeneity. Even at the same
site of glycosylation, diverse glycans with different linkages,
number of antenna, and monosaccharide compositions are
possible, giving rise to challenges in separation (chromatog-
raphy) and isomerization (mass spectrometry).
A common glycosylation in mAbs is N-glycosylation where
the glycans are linked to the nitrogen of the Asn residue of
the protein with a consensus sequence Asn-X-Ser/Thr or,
more rarely, Asn-X-Cys where X is any amino acid except
proline. Moreover, N-glycans have a common five-membered
trimannosyl chitobiose core, Man1–6(Man1–3)Man1-
4GlcNAc1–4GlcNAc1-Asn-X-Ser/Thr. The highly complex
nature of N-glycosylation analysis has given rise to a pro-
liferation of different methods (1–14). Currently, N-glycosy-
lation is examined at the level of intact proteins, protein
fragments, peptides, glycans, or monosaccharides. Ana-
lytes are then analyzed by mass spectrometry (MS)1 (1);
liquid chromatography (LC) with fluorescence detection
(FD)(2) and/or MS detection; capillary electrophoresis (CE)
with MS detection (3); CE-laser-induced fluorescence de-
tection (CE-LIF); high performance anion exchange chroma-
tography with pulsed amperometric detection (HPAEC-
PAD); nuclear magnetic resonance (NMR) spectroscopy; or
a combination of these techniques (4).
One popular approach is the release of glycans where
N-glycans are cleaved from proteins using Peptide-N-Glyco-
sidase F (PNGase F), which hydrolyzes the side-chain amide
group of the glycosylated asparagine. Before analysis, gly-
cans may be subjected to permethylation, reduction, or fluo-
rophore labeling to increase sensitivity and specificity. Struc-
ture elucidation and isomer separation is possible using the
glycan-release approach, but it lacks information on the site
of glycosylation because analysis is performed after the gly-
cans are cleaved from the protein.
1 The abbreviations used are: MS, generic mass spectrometry or
first stage mass spectrometry; AA, aminobenzoic acid; AB, amino-
benzamide; APTS, 9-aminopyrene-1,4–6-trisulfonate; C4, C4 (butyl)
desalting column; C8, C8 (octyl) desalting column; CE, capillary elec-
trophoresis; CFG, Consortium for Functional Glycomics; DI, direct
infusion; Exo, exoglycosidase; Fab, antigen-binding fragment of a
monoclonal antibody; Fc, crystallizable fragment of a monoclonal
antibody; FD, fluorescence detection; GU, glucose units; HILIC, hy-
drophilic interaction liquid chromatography; HPAEC-PAD, high per-
formance anion exchange chromatography with pulsed amperomet-
ric detection; IC, ion chromatography; IdeS, immunoglobulin
G-degrading enzyme; LC, liquid chromatography; LIF, laser-induced
fluorescence detection; LoR, limit of reporting; mAb, monoclonal
antibody; MALDI, matrix-assisted laser desorption/ionization; MRV,
minimum reported value; MS/MS, tandem mass spectrometry; MSn,
nth stage MS; MT, migration time; ND, not detected; NISTIR, NIST
internal report; NMR, nuclear magnetic resonance; NQ, not quanti-
fied; PA, peak area/integration; PGC, porous graphitized carbon; PH,
peak height; PNGase F, Peptide-N-Glycosidase F; PS, primary sam-
ple; RP, reversed-phase; RT, retention time; SEC, size-exclusion
chromatography; UOXF, Oxford Glycobiology Institute; xCGE, multi-
plexed capillary gel electrophoresis.
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Analysis of glycopeptides can provide glycosylation site
information along with glycan compositions. In this approach,
mAbs are digested with proteases such as trypsin (and less
commonly used enzymes such as chymotrypsin, LysC, LysN,
AspN, GluC, or ArgC) to produce peptides and glycopeptides
that are then typically analyzed using MALDI-MS and LC-
MS(/MS) methods (and less commonly CE-MS(/MS) methods
(15)). The peptide attached to the glycoform gives information
on the site of glycosylation. Potential disadvantages include
challenges in differentiating isomers and suppression of gly-
copeptide ions because of peptide ions at the precursor
(MS1) level. The latter could be alleviated by (two-dimen-
sional) LC or enrichment methods (16).
Middle-down and top-down approaches characterize the
glycosylation by analyzing protein fragments and intact pro-
teins, respectively. In the middle-down approach, mAbs are
treated with immunoglobulin G-degrading enzyme (IdeS), an
endopeptidase that cleaves heavy chains below the hinge
region, resulting in antigen-binding (Fab) and crystallizable
(Fc) fragments. These large fragments are then usually ana-
lyzed by MS. Protein fragments have a lower molecular mass
than the intact protein and could be better resolved in MS
compared with the analysis of intact mAbs in the top-down
approach. Compared with other techniques, the top-down
approach provides the advantage that little-to-no sample
preparation steps are needed before the analysis. Typically,
only desalting of the intact mAb is necessary, which is nor-
mally performed with a desalting column (e.g. C4, C8) fol-
lowed by the analysis with MS. However, because top-down
and middle-down analyses often result in higher masses,
fewer glycan compositions can be distinguished because of
lack of resolution compared with other MS-based methods.
The diversity of these methods presents a major challenge
in the interpretation of N-glycosylation measurements. Unfor-
tunately, only a few multi-laboratory studies have been re-
ported assessing the performance of the different approaches
(17–21). In two studies by the Human Proteome Organization
(HUPO), relative abundances of N-glycans (in transferrin and
IgG) (17) and O-glycans (in IgA1) (18) were analyzed by 20 and
15 laboratories, respectively. They observed that MS-based
methods are efficient in identifying and quantifying glycans.
However, there were no participants from biopharmaceutical
companies.
Here we present the design and results of our interlabora-
tory study of two materials: primary sample (PS) 8670, com-
monly referred to as NISTmAb (22), and mod-NISTmAb, a
material derived from PS 8670 by modification with galacto-
sidase. PS 8670 is the in-house standard for NIST Reference
Material 8671 (23). The rationale for the use of these samples
is presented in supplementary Discussion S2. This report is
based on 103 reports submitted by 76 laboratories worldwide.
It builds on the NIST internal report (NISTIR) 8186 (24).
This interlaboratory study had two goals. The first goal was
to determine measurement variability in identifying and quan-
tifying N-glycosylation in monoclonal antibodies across labo-
ratories in the glycomics and glycoproteomics community,
including laboratories form biopharmaceutical companies and
universities. The second goal was to aid in determining com-
munity-based consensus medians for the glycosylation of the
PS. The community’s consensus values for NISTmAb PS
8670 glycosylation, robustly estimated as medians, represent
an unparalleled diversity of approaches applied to the same
material and serve as a seminal baseline for comparing gly-
coanalytical strategies.
Finally, we note two quite different levels of identification -
by composition and by structure. Compositions are deter-
mined by high mass accuracy mass spectrometry, whereas
confident isomer identification often requires reference mate-
rials or chromatographic retention matching.
EXPERIMENTAL PROCEDURES
Monoclonal Antibody Sample Preparation—Two materials were
used in the study, (1 the Primary sample (PS) for NIST Reference
Material 8671, NISTmAb, Humanized IgG1 Monoclonal Antibody
produced in NS0 cells, and (2 a material derived from the PS by
treatment with galactosidase, termed “mod-NISTmAb.”
NISTmAb was obtained as a bulk substance prepared using mam-
malian cell culture and downstream processing. It has one N-glyco-
sylation site at the Fc region of the antibody. mod-NISTmAb was
prepared by subjecting a portion of NISTmAb to -1,4-galactosidase
(New England Biolabs, Ipswich, MA) and then adding the resulting
solution back to the original NISTmAb (30:70 by mass).
Study Execution—The study was conducted in two stages: Stage
1 involved nine selected laboratories who volunteered to assist in final
study design; Stage 2 was widely advertised and open to all labora-
tories. Two samples were shipped to laboratories on June 2015 and
August-September 2015 for Stage 1 and Stage 2, respectively. Lab-
oratories received three vials consisting of two blinded monoclonal
antibody samples and one buffer solution in 1.0 ml screw-top tubes
(Matrix™ Thermo Fisher Scientific, #3740) as follows:
• Sample A: white label, frozen liquid, 0.4 mg, 100 mg/ml mAb
• Sample B: blue label, frozen liquid, 0.4 mg, 100 mg/ml mAb
• Buffer: yellow label, frozen liquid, 1 ml, 25 mmol/L L-Histidine,
pH 6.0
Laboratories were informed that both samples are humanized
IgG1k expressed in murine suspension culture and that the samples
are “drug-like substances” not for human use. The buffer solution was
provided as a diluent.
Participants used their method of choice to determine the glycan
content in the two samples. Participants were requested to provide
measurement results using NIST-provided data and method reporting
templates (24) by July 30, 2015 (Stage 1) and November 6, 2015
(Stage 2). Some laboratories submitted more than one report; each
report was assigned a confidential laboratory number (and was
treated as a separate laboratory). Participants could enter other gly-
cans or methods in the template; no other post-translational modifi-
cations, e.g. lysine glycation, could be reported.
Data were analyzed as reported, i.e. no normalization, using a
variety of robust statistical analysis techniques to assess measure-
ment reproducibility and to characterize glycan distributions. Results
were compiled and evaluated for determination of community’s con-
sensus medians, within-laboratory precision, and concordance within
the laboratories. A technical summary (24) of reported and derived
values from all laboratories, a table of all identified glycans, and an
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individualized graphical analysis of their performance for the exercise
were sent to the participating laboratories on June 2, 2017.
Shipping—Package shipped to each laboratory consisted of three
vials (Sample A, Sample B, and L-Histidine buffer solution) and a
welcome packet (24). The three vials were stowed in a rolled, self-
sealing bubble wrap bag and placed in an insulated box filled with dry
ice. The welcome packet consisted of a cover letter; instructions;
packing list/shipment receipt confirmation form; and data, method,
and comment reporting sheets. These documents were enclosed in a
waterproof sleeve and placed at the top of the shipping box, between
the cardboard covering and the foam insulation. A soft copy of the
welcome packet was emailed to participants as one spreadsheet
workbook with multiple worksheets. Participants were requested to
return the filled shipment receipt confirmation form as soon as they
received the shipped package.
Analysis Methods—Each laboratory was asked to perform glyco-
sylation analysis of the two samples in triplicate using their own
method(s), as summarized in Table I. Briefly, glycans were cleaved by
incubating mAbs with PNGase F (74 reports), trypsin/PNGase F (1
report), and Pepsin/PNGase A (1 report). Cleaved glycans were de-
rivatized using fluorescent (54 reports) or non-fluorescent (22 reports)
methods. Next, glycans were separated with chromatography (CE (5
reports), HILIC (46 reports), IC (1 report), PGC (6 reports), RP (6
reports)) or without chromatography (12 reports), and then identified
by various analytical methods.
Glycopeptides were cleaved from mAbs using trypsin (21 reports).
Cleaved glycopeptides were left underivatized (18 reports) or sub-
jected to dimethylamidation (1 report), Ludger V-tag (1 report) or
reduction (1 report). Glycopeptide separation was performed using
RP (17 reports), HILIC (1 report) or CE (1 report) chromatography. MS
(20 reports) or FD (1 report) was used for analysis.
To obtain protein fragments, Ides (2 reports) or Endo-S (1 report)
enzymes were added to mAbs. No derivatization was performed
before chromatography using CE (1 report), RP (1 report), or SEC (1
report). Analysis was performed using LC-MS. Intact mAbs were
analyzed with (1 report) or without PNGase F (1 report) and with (1
report) or without RP (1 report) chromatography. Intact mAbs analysis
was performed using MS.
Laboratories recorded in a provided template a) methods used and
b) percent abundances of glycans. Laboratories were asked to create
separate reports for each method of analysis. If a value obtained was
below their limit of detection or quantification, participants were
asked to indicate this result as “ND” (not detected) or “NQ” (not
quantified), respectively.
Describing Glycans in the Data Reporting Template
Naming Conventions—Currently, there is no standard way of nam-
ing N-glycans. Common names using the G0F and Oxford naming
conventions were used. In cases where, to the authors’ knowledge,
there is no existing name for a glycan, every attempt was made to
derive it from naming conventions, summarized below.
Common Name—
1. All N-glycans have two core GlcNAcs;
2. High mannose glycans are named ManX where X is the number
of mannoses after the two core GlcNAcs;
3. F is fucose, number after F indicates number of fucoses. No
number indicates the presence of core fucose only;
4. Gx is galactose and x is the number of terminal Gal connected to
two GlcNAcs, G0 is a biantennary complex glycan with two
terminal GlcNAcs, G1 is a biantennary complex glycan with two
GlcNAcs and one terminal Gal, G2 is a biantennary complex
glycan with two GlcNAcs and two terminal Gal;
5. Gx-yN means y GlcNAc is missing, e.g. G1-N is biantennary
complex glycan with one terminal GlcNAc and one terminal Gal;
6. S (NeuAc) or (NeuGc) is sialic acid. (NeuAc) or (NeuGc) indicates
type of sialic acid;
7. Number in parenthesis indicates linkage: F(6) or S(6) means a
1–6-linked core fucose or 2,6-linked sialic acid, respectively;
8. Number in square brackets is the location of residue, e.g. (3) or
(6) indicates that the residue is in the 1,3 or 1,6 mannose arm,
respectively; and
9. xaGal is -1,3-linked galactose, x is the number of residues;
Oxford Name—
1. All N-glycans have two core GlcNAcs;
2. F at the start of the abbreviation indicates a core fucose, (6) after
the F indicates that the fucose is 1–6 linked to the inner
GlcNAc;
3. Mx, number (x) of mannose on core GlcNAcs;
4. Ax, number of antenna (GlcNAc) on trimannosyl core; A2, bian-
tennary with GlcNAcs as 1–2 linked; A3, triantennary with a
GlcNAc linked 1–2 to both mannose and the third GlcNAc
linked 1–4 to the 1–3 linked mannose; A3, triantennary with
a GlcNAc linked 1–2 to both mannose and the third GlcNAc
linked 1–6 to the 1–6 linked mannose; A4, GlcNAcs linked as
A3 with additional GlcNAc 1–6 linked to 1–6 mannose;
5. B, bisecting GlcNAc linked 1–4 to 1–3 mannose;
6. Gx, number (x) of linked galactose on antenna, (4) or (3) after the
G indicates that the Gal is 1–4 or 1–3 linked; [3]G1 and [6]G1
indicates that the galactose is on the antenna of the 1–3 or
1–6 mannose;
7. Gax, number (x) of linked alpha galactose on antenna; and
8. Sx, number (x) of sialic acids linked to galactose; the numbers 3
or 6 in parentheses after S indicate whether the sialic acid is in
an 2–3 or 2–6 linkage.
Monosaccharide Composition—The monosaccharide composition
is inside a square bracket. Small letters were used to avoid confusion
with elements (hydrogen, nitrogen, fluorine, etc.): h  hexose, n 
N-acetylhexosamine, f  deoxyhexose (e.g. fucose), a  NeuAc, g 
NeuGc. Number after the letter denotes the number of residues. For
example, [h6n4f1a1] has 6 hexoses, 4 N-acetylhexosamine, 1 fucose,
1 NeuAc. For sulfonated glycans, S  sulfur.
Structure Conventions—Two structure notations were used: the
Consortium for Functional Glycomics (CFG) (25) and the Oxford Gly-
cobiology Institute (UOXF) notations. Glycoworkbench 2.1 (Eurocarb)
(26) was used to draw the structures. The differences are in the
monosaccharide residue representations (for example, NeuAc is pur-
ple diamond in CFG but purple star in UOXF notations) and linkage
notations (angle represents linkage in UOXF). A revised CFG format
has been introduced but it was not used in this reporting template.
Calculations for Derived Attributes of NISTmAb—Calculations for
the glycan attributes were estimated from the median results and
based on an earlier reported method (27):
• Galactosylation  Sum of (% abundance)(galactosylation fac-
tor) for all glycans with terminal galactose where the factor is the
fraction of antennae that are galactosylated. For example, the
galactosylation factor of G0F is 0, G1F is 0.5, G2F is 1.
X  Galactosylation  As above but for  galactosylation only
• Sialylation  Sum of (% abundance)  (sialylation factor) for all
glycans with NeuAc or NeuGc sialic acid where the factor is the
fraction of antanaee that are sialylated.
X NeuAc sialylation  As above, but for NeuAc only
X NeuGc sialylation  As above, but for NeuGc only
• Fucosylation  Sum of (% abundance) for all glycans with fu-
cose residues.
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X Core fucosylation only  Sum of (% abundance) for all gly-
cans with 1 fucose. This calculation assumes that the first
fucose is always a core fucose.
X Difucosylation  Sum of (% abundance) for all glycans with 2
fucose residues.
• Bisecting GlcNAc  Sum of (% abundance) for all glycans with
bisecting GlcNAc.
• High mannose level  Sum of (% abundance) for all high-
mannose glycans.
• Sialic Acid/Galactose ratio  Sialylation/Galactosylation.
RESULTS
Overview—Because the participating labs selected their
own methods of analysis and these methods can differ in
many ways, merits and drawbacks of the methods can only
be discussed in general terms. There are two principal factors
distinguishing output: the number of different glycans re-
ported and how the structures of those glycans were deter-
mined. High mass accuracy mass spectrometry is currently
capable of determining compositions of glycans over a wide
range of abundance and therefore can yield the largest num-
ber of different glycans, it is limited in isomer identification
because spectra of different isomers are often indistinguish-
able and do not generally contain sufficient information for full
structure determination. For example, glycopeptide fragmen-
tation appears incapable of yielding complete glycan struc-
tural information. On the other hand, defined structures may
be determined using chromatographic methods, coupled with
standard materials and labeling or use of enzymes (exoglyco-
sidases) capable to removing selected outer glycans. How-
ever, only a limited number of standard glycans are available
and enzymatic methods are of limited use in complex glycan
mixtures. In the absence of direct structural information,
structures are generally represented based on biological in-
ference, which are, in effect, informed guesses.
Sample preparation methods, ranging from enzymatic gly-
can release and labeling to protein digestion constitute a
major source of variation. The effectiveness of these methods
depends as much on laboratory skill than specific method and
are, in effect, a hidden source of variation in these studies.
Differences in the objectives of the labs is a major contrib-
utor to the diversity of methods and results. Probably the
most critical measurements are made by biopharmaceutical
companies who rely on glycan determinations for both prod-
uct quality and government approval. Consequently, they
generally use well-established, conservative methods that of-
ten involve several targeted, derivatized glycans with pre-
cisely defined established chromatographic methods. Fur-
ther, they may limit their number of analytes to only the major
glycans considered. Other groups, such as instrument com-
panies and some academic institutions seek to maximize the
number of glycans identified, which generally sacrifices struc-
tural information. Other labs made these measurements for
various educational and internal quality control purposes
whereas others wish to develop or demonstrate new methods
of analysis.
Demographics of Laboratories—One hundred eighteen lab-
oratories responded to the call for participation. However,
because of challenges with timing, personnel, shipping (bad
weather, customs delay), legal, technical (instrument, freezer
malfunction), and other issues, several laboratories had to
drop out of the study. Samples were sent to 90 laboratories;
76 laboratories submitted 103 reports. Supplemental Fig. S1A
shows a map of the participating laboratories from Europe
(42%) and North America (38%), Asia (18%), and Australia
(2%). Laboratories were primarily from the industry sector, with
almost half of these laboratories from biopharmaceutical com-
panies, as shown in supplemental Fig. S1B.
Glycosylation Analysis Methods Used by Participating Lab-
oratories—Table I summarizes the glycosylation analysis
methods used by laboratories in this study. Out of 103 re-
ports, 74% analyzed released glycans, 20% used glycopep-
tides, and 6% used intact protein and protein fragments.
Fluorescently-labeled glycans were commonly analyzed by
LC-FD or LC-FD-MS methods except for APTS-labeled gly-
cans, which were analyzed by CE-LIF exclusively. Reduced
and permethylated glycans were analyzed solely by MS (using
MALDI, direct infusion- (DI) and LC-electrospray ionization
techniques). Hydrophilic interaction liquid chromatography
(HILIC) is the commonly used chromatographic method for
glycans labeled with 2-AB, glycosylamine, and procainamide
fluorophores whereas porous graphitized carbon (PGC) was
used for reduced glycans.
In Table I, glycopeptides were typically analyzed without
derivatization (18 out of 21 reports) by reversed-phase LC-MS
(16 out of 21 reports). MS techniques (MS mass, MS/MS
fragmentation data, or a combination) were frequently used
for identification whereas MS peak area, MS intensity, and
summation of isotope peaks were used for quantification.
Supplemental Fig. S2 shows an example of fragmentation
data of glycopeptides using LC-MS/MS analysis. HCD spec-
tra at 40% normalized collision energy (supplemental Fig.
S2A) shows the peptide backbone (supplemental Fig. S2B),
oxonium ions (supplemental Figs. S2C and S2J), and glycan
fragmentation (supplemental Fig. S2D–S2I). Oxonium ions
have been used to screen for the presence of glycopeptides
and glycan motifs (28,29). The laboratory used oxonium ions
from a HexNAc (m/z 168.07, m/z 186.08, and m/z 204.09) to
screen for the presence of glycopeptides (supplemental Fig.
S2C). Presence of m/z 512.20 oxonium ion is specific for
antenna fucosylation (30) (supplemental Fig. S2E); m/z 290.09
and m/z 308.10 oxonium ions are specific for NeuGc resi-
dues (supplemental Fig. S2F); and m/z 528.19 is indicative
of a trisaccharide having 2 hexoses and 1 N-acetylhexo-
samine., e.g. Gal-Gal-GlcNAc (supplemental Fig. S2G and
S2H). For high mannose glycans, the absence of GlcNAc
antenna could result in hexose oxonium ions m/z 127.04,
m/z 145.05, and m/z 163.06 (supplemental Fig. S2J). The
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laboratory screened glycopeptides for high-mannose gly-
cans using m/z 163.06.
Intact proteins and protein fragments were analyzed mostly
using LC-MS, as shown in Table I. Separation was performed
by CE, RP, SEC, or PGC; identification was performed by MS
mass or MS/MS fragmentation with exoglycosidases; and
quantification by MS intensity.
Supplemental Table S1 lists the analytical approaches by
laboratory sector. Here, a disparity could be observed in the
choice of methods. Biopharmaceutical company laboratories
preferred the well-established method involving fluorophore-
labeled glycans for their analysis (19 out of 21 laboratories);
whereas two used glycopeptide analyses. University labora-
tories, however, primarily used either more generic mass
spectrometry-based methods of glycopeptide analysis (14
out of 32 laboratories) or non-fluorescent glycan (12 out of 32
laboratories) approaches. Protein fragment (n  3) and intact
protein (n  2) techniques were used to demonstrate the
technology - they are not listed in supplemental Table S1 to
protect laboratory anonymity.
Glycan Identification—The data reporting template (24) in-
cluded 54 glycan compositions for 68 glycan structures, how-
ever an additional 62 compositions and 71 other structures
were reported by the participating laboratories. A total of 116
compositions and 139 structures were identified. Supplemen-
tal Table S2 lists the glycan compositions and isomers iden-
tified by laboratories in this study (24). Supplemental Table S3
lists all the quantified and derived values for NISTmAb and
mod-NISTmAb for glycan compositions and glycan struc-
tures (24). Independent of this study, glycosylation of NIST-
mAb was previously characterized by three laboratories
using HILIC with fluorescence detection of 2-AB-labeled
N-glycans and collectively found 24 glycan peaks (28, 31).
Another work using 1D- and 2D-LC-MS/MS for the analysis
of glycopeptides found 60 glycan masses on NISTmAb
(16).
The number of glycan compositions reported by each lab-
oratory ranged from 4 to 48. Most reports listed about the
same number of glycan compositions for each of the two
samples. Fig. 1 summarizes the number of unique glycan
compositions reported for NISTmAb and/or mod-NISTmAb
samples as a function of the laboratory’s analytical method,
analyte, and organizational type. On average, more compo-
sitions were reported by laboratories (1 using MS-based
methods, (2 analyzing glycopeptides, and (3 that were uni-
versity-based. However, the wide range in the number of
compositions reported within most of the groups suggests
that the technology is not the major determinant.
Fig. 2 summarizes the proportion of compositions that
were reported with isomeric information as a function of
identification method. On the average, laboratories that
used exoglycosidases reported the greatest number of iso-
meric information, followed by retention times, then by FD,
then by MS/MS. Surprisingly, about one-fourth of the data
sets that nominally used accurate mass (MS) identification
identified some isomers.
Glycan Quantification—Laboratories were asked to report
quantitative values for each glycoform as proportions relative
to the sum of all glycoforms detected. Table II lists the con-
sensus median abundances of glycan compositions and gly-
FIG. 1. Number of unique glycan compositions reported, grouped by method, analyte, and sector. The boxes span the central 50% of
reported values, 25% to 75%; the whiskers span the central 90%, 5% to 95%; the central line marks the median, 50%. Box widths are
proportional to the number of reports. Groups within each category are presented in order of decreasing number of reports. Solid circles
represent individual results within categories of fewer than six reports. The dotted line marks the median number of compositions reported in
the 103 reports provided by 76 laboratories.
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can structures on NISTmAb that were reported at least six
times. The three compositions [h3n4f1], [h4n4f1] and [h5n4f1]
are the most commonly reported and the most abundant
compositions; together, they account for more than 85% of
the total signal intensity. Although the normalization factors
(the sum of signals) for the different data sets are not based
on the same compositions nor the same number of compo-
sitions, the dominance of [h3n4f1] and [h4n4f1] ensures that
the reported proportions are comparable across data sets.
However, the differences among the normalization factors are
a source of variability. Other approaches such as normalizing
to the most abundant few glycoforms could be pursued in
future studies.
Laboratories were asked to report their results as percent
abundances normalized such that they summed to 100% per
sample. Supplemental Fig. S3 shows a histogram of the sum
of the unique glycan composition values for NISTmAb and
mod-NISTmAb as reported by the laboratories (n  206, two
samples per laboratory). Although results in most data sets
summed to 100%, the sums ranged from 88% to 122%.
Some laboratories assigned percent abundances to uniden-
tified glycans; the sum of these values was reported as one
entry called “Unknown Glycans” and added to the abundance
sum for that sample.
The number of replicate values per reported composition or
structure per sample ranged from one to nine. The nature of
these values ranged from purely technical replicates (multiple
measurements of the same preparation) to process replicates
(single measurements of multiple independent preparations).
In all cases where two or more replicate values were reported,
the values were summarized as their mean and standard
deviation (SD).
Some data sets reported replicate values equal to zero, not
detected (ND), and not quantified (NQ). These values can be
ignored when there are no quantitative values in a set of
replicates but cause numerical instability when there is at
least one quantitative value in the set. Various options were
explored for handling these situations in a uniform manner
including: treating non-numerical results as zero, replacing
zeros and non-numerical values with the data set’s minimum
reported value (MRV, the smallest reported numerical value of
a data set), or replacing them with the data set’s limit of
reporting (LoR, the extrapolated smallest value of a data set).
Replacement with the LoR provided slightly smaller SDs than
replacement by the MRV. Supplemental Fig. S4 shows the
LoR for one set of results. Gray lines are traces of the unique
non-zero values reported in each set of results, where the
numbers are ordered by decreasing value. If the true amounts
of the minor glycans are randomly distributed and all results
reflect the same level of analytical effort, a best-fit line to the
right-tail of the trace estimates the LoR for that set. As shown
in supplemental Fig. S5, most of the LoRs agree well for MRVs
above about 0.05%. Below this value, many of the sets con-
tain a few values many-fold smaller than their LoR. This may
reflect special interest in selected glycan components rather
than reporting issues with the less-abundant glycans. The LoR
values in the data set may be more representative of the ana-
lytical sensitivity of a measurement system than is the MRV.
Derived Attribute Quantities in NISTmAb—Table III shows
the degree of galactosylation, sialylation, fucosylation; levels
of bisecting GlcNAc and high-mannose; and the sialic acid/
galactose ratio in NISTmAb. These values are estimated from
the consensus median values of the glycan compositions. Cal-
culations are based on previous works by Wuhrer (27) and are
designed to reflect biosynthetic pathways (32) and, to some
extent, enzyme activity. In addition, these glycosylation
traits relate to differences in effector functions of monoclonal
antibodies and circulation half-time for other therapeutic glyco-
proteins.
All antennae were assumed to be available for galactosyla-
tion by most galactosyltransferases. Antennae galactosylation
may be a reasonable proxy for enzyme activity and may
therefore reflect regulation of galactosylation process in a
biological system. Thus, galactosylation levels were ex-
pressed by calculating the number of galactosylated (occu-
pied) antennae divided by the total number of antennae of the
specific glycan. Only glycans identified with galactose resi-
dues were included in the calculations. For biantennary gly-
cans, the galactosylation levels are 0.0, 0.5, and 1.0 for 0, 1,
and 2 galactoses, respectively. For triantennary glycans, the
galactosylation levels are 0.0, 0.33, 0.67, and 1.0, reflecting
the presence of 0, 1, 2, or 3 galactosylated antennae. For
NISTmAb, the median degree of galactosylation is 36.2% with
alpha-galactosylation at 3.8%, as shown in Table III.
FIG. 2. Proportion of glycan compositions reported as isomers.
The boxes span the central 50% of reported values, 25% to 75%; the
whiskers span the central 90%, 5% to 95%; the central line marks the
median, 50%. Box widths are proportional to the number of reports.
Categories are presented in order of increasing median proportion.
The dotted line marks the median proportion of compositions re-
ported as isomers.
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TABLE II
Community’s consensus abundances of glycans in NISTmAb PS 8670 reported by laboratories at least six times. Glycan compositions are
arranged by decreasing number of values (N). Supplementary Table S2 lists all glycan structures and names. Supplementary Table S3 lists all
the community’s consensus values
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TABLE II—continued
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TABLE II—continued
n  number of values; consensus median  consensus median (50th percentile or 2nd quartile, expressed as percent of total composition)
of the distribution of the reported results; MADE  median absolute deviation; Srep  a robust estimate of the expected repeatability, the
median SD for glycan compositions with at least six results; CV  robust coefficient of variation (MADE/median); CVrep  (Srep/median).
ER: NISTmAb Glycosylation Interlaboratory Study
22 Molecular & Cellular Proteomics 19.1
 by guest on January 20, 2020
https://w
w
w
.m
cponline.org
D
ow
nloaded from
 
For sialylation levels, the same principle is applied, i.e. the
sialylation per antenna was calculated. For NISTmAb, NeuAc
and NeuGc sialylation were observed at a medium value of
1.3% and 2.2%, respectively. The ratio of sialic acid per
galactose was calculated as 0.1%. This value reflects the
sialylation activity, i.e. whether available acceptor positions
have been sialylated.
Monofucosylation was interpreted as core fucosylation.
NISTmAb had very high levels of core fucosylation (median of
104%; values exceeding 100% are artifacts of the variable
normalization factors). The antenna fucosylation (manifested
as difucosylation) at 0.38% was calculated separately be-
cause the interaction between core and antenna fucosylation
is assumed to be minimal.
Issues with Glycosylation Analysis Methods—Laboratories
reported challenges in identifying and quantifying glycans.
Some laboratories reported their analysis at the composition
level only and did not differentiate isomeric species; some
laboratories analyzed at the glycan isomer level and had
challenges in identifying co eluting or same mass species.
These issues are usually method dependent, as shown in
supplemental Table 4. Some glycan structures were sup-
ported by MS/MS and other structures were inferred from
similar structures, e.g. triantennary structures. Consequently,
some abundance values were assigned to triantennary struc-
tures instead of bisecting glycans. The same laboratory ob-
served a discrepancy for glycan G1FS N (NeuGc). Compared
with quantitative data from subunit analysis, the glycopeptide
abundance was higher than subunit abundance. Overall, the
laboratory observed that glycopeptide abundances were in
good accordance with the subunit data with slightly lower
values for G0F and G1F in the glycopeptide analysis.
One laboratory analyzed protein fragments by LC MS that
had masses up to 25 kDa. One or two nominal mass differ-
ences were challenging to distinguish using their technique.
Another laboratory analyzed 2-AB glycans using HILIC LC
FD with comparison to retention time of standards. It was
difficult to distinguish glycans that coelute, e.g. G2 and Man6.
Moreover, the laboratory was unable to identify glycan peaks
present in the samples but absent in their lab-designated
standard sample.
Supplemental Table S4 lists the advantages of certain
methods as described by laboratories. Sialic acid specific
derivatization of 2-AB or ethyl esterified glycans analyzed by
LC FD or MALDI MS could confirm presence of terminal 2 6
linked NeuGc in glycans.
Intact protein analysis could give the G0F/G1F, G1F/G2F,
G0/G0F, G0F N/G0F, G2F1aGal/G2F glycoforms present in
the monoclonal antibodies. Due to the cleavage of glycopep-
tides or glycans from the protein, analysis using these two
analytes could not provide this specific information.
2-AB glycans analyzed by LC FD using glucose units and
APTS labeled glycans analyzed by multiplexed capillary gel
electrophoresis (xCGE) using migration time of standards and
exoglycosidases could distinguish between isomers.
Additional Information on NISTmAb
Some laboratories performed unique analyses, resulting in
additional information on the glycosylation of NISTmAb
Absolute Glycan Amounts—One laboratory determined ab-
solute glycan amounts in the samples by employing isotopic
dilution methods, using 13C-labeled N-glycans as internal
standards followed by MALDI-TOF MS analysis. For example,
the absolute amounts of three glycans in NISTmAb were
reported to be:
G0Fa: (626.7  7.5) pmol per 100 g NISTmAb
G2F: (110.8  5.9) pmol per 100 g NISTmAb
G2: (19.0  3.8) pmol per 100 g NISTmAb
Glycoforms in Intact Samples—One laboratory analyzed
intact mAb samples using LC-MS and identified glycoforms
on the two Fc portions that were analyzed. Example glyco-
forms are G0/G0F, G0F/G1F, G1F/G2F, G0F-N/G0F, and
G2F1aGal/G2F. Abundance values for these glycoforms are
shown in supplemental Table S3, bottom rows.
Unknown Modifications—One laboratory found an un-
known delta mass of  1856 Da at 0.40% abundance in
NISTmAb by LC-MS. Another laboratory detected  54 Da
unidentified protein modification using 1H-NMR and MS. The
latter found a glycan present in 3% with no branching at the
central -Mannose, i.e. there is only one arm present with a
terminal NeuGc and a proximal Fuc.
Unglycosylated Forms—One laboratory used protein frag-
ment analysis by C4-LC-MS and observed the unglycosylated
form of the samples at 0.60% abundance in NISTmAb. An-
other participant used glycopeptide analysis by C18-LC-MS
and detected the unglycosylated form at 0.91% abundance in
NISTmAb, as confirmed by high mass accuracy MS ( 3 parts
per million (ppmb) mass deviation).
a Definition of naming convention of glycans is in the Experimental
Procedures section.
b ppm is a unit of mass measurement error (m/z)/(m/z) * 1000000,
expressed as unified atomic mass units (Daltons) divided by charge.
TABLE III
Derived attribute quantities for NISTmAb PS 8670, estimated from the
consensus median values of the glycan compositions
Features
Number
of Labs
25% Median 75%
Galactosylation 32 31.78 36.21 43.30
alpha-Galactosylation 13 3.00 3.77 4.97
Sialylation 18 2.26 3.48 6.98
NeuAc sialylation 6 0.71 1.25 2.83
NeuGc sialylation 12 1.55 2.23 4.16
Core fucosylation only 37 92.36 103.95 118.23
Antenna fucosylation 3 0.25 0.38 0.73
Bisecting GlcNAc 7 1.49 2.17 3.83
High mannose 6 1.04 1.92 3.42
Sialic Acid/Galactose Ratio 0.07 0.10 0.16
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Glycan Motifs—One laboratory employed lectin microar-
rays on intact proteins (33). The participant found that NIST-
mAb has more core fucosylation whereas mod-NISTmAb has
slightly more terminal fucosylation. Both samples hint at the
presence of 2,6 sialylation and show similar patterns for
hybrid/lower order mannose N-glycans, indicating no strong
presence of complex glycans.
DISCUSSION
Sample Ratios Demonstrate Comparability—To examine
the between-data set differences in the measurements of the
two samples, mod-NISTmAb/NISTmAb ratios were calculated
for the 57 glycan compositions that were reported at least six
times for either NISTmAb or mod-NISTmAb. Since the num-
ber and identity of the reported glycan compositions in the
two samples were nearly the same within each data set, these
ratios are insensitive to the normalization factors. Figs. 3A and
3C display the NISTmAb and mod-NISTmAb measurement
distributions of these compositions as boxplots. Fig. 3B dis-
plays the mod-NISTmAb/NISTmAb ratios. Supplemental Ta-
ble S3 lists the values of these ratios.
Every box in Fig. 3 spans the central 50% of the reported or
calculated values, with the horizontal middle line denoting the
consensus median. The compositions are sorted in order of
increasing mod-NISTmAb/NISTmAb median. The width of
each box is proportional to the square root of the number
of values defining the distribution, so the wider the box, the
more laboratories reported that glycan. For example, 102 of
the 103 data sets identified [h3n4f1] and [h4n4f1], which have
the widest boxes. The dashed red line in Fig. 3B denotes the
expected ratio, 1.0, when a glycan result is the same in
mod-NISTmAb as it is in NISTmAb. Ideally, glycan structures
with terminal 1,4-gal should fall below this red line because
1,4-galactosidase, an enzyme that specifically cleaves ter-
minal 1,4-gal, was added to a portion of the mod-NISTmAb.
Glycan compositions colored red in the x axis have terminal
1,4-gal as their dominant structure. As expected, most of
these glycans fall below the red line, i.e. they have lower
abundance in mod-NISTmAb than in NISTmAb.
Fig. 3D displays the average variability and bias of the
mod-NISTmAb/NISTmAb ratios relative to the consensus me-
dians in a form sometimes called a “targetplot” (34). Each dot
FIG. 3. Summary results for the 57 most frequently reported unique glycan compositions. Box plots for A) mod-NISTmAb, B)
mod-NISTmAb/NISTmAb ratio, and C) NISTmAb PS 8670. Glycan compositions in red have terminal 1,4-gal as their dominant structure. Each
box represents the distribution of the central 50% of the mean of the reported replicate values for one glycan. The horizontal middle line in each
box represents the consensus median. The width of each box is proportional to the square root of the number of values defining the
distribution. The dashed red line in the display of the Fig. 3B denotes the expected ratio, 1.0, when a glycan result is the same in mod-NISTmAb
as it is in NISTmAb. Glycans are sorted in order of increasing mod-NISTmAb/NISTmAb ratio. D) Targetplot summary of mod-NISTmAb/
NISTmAb ratios relative to the consensus medians. Each dot represents one set of results. Dot diameter is proportional to number of
mod-NISTmAb/NISTmAb ratios reported. The dots are color-coded by distance from the (0, 0) origin: dots within two comparability units are
colored green, between two and three units are colored yellow, and greater than three units are colored red. The “Z-score Mean” axis displays
the average bias estimated as the mean of the “Z-score” values of the ratios. The “Z-Score SD.” axis displays the variability of individual bias
estimates, estimated as the standard deviation of the Z-scores.
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marks the summary score for the unique glycan compositions
in one set of results. The vertical axis displays the mean bias
or “concordance” of the ratios: zi  (j(xij 	 x j)/sj)/nj, where xij is
the ratio for the jth composition reported in the ith data set, x j
is the consensus location of the jth composition, sj is the
consensus dispersion for that composition, and nj is the num-
ber of data sets that report values for that composition in both
samples. Because the distributions of the ratios for most
compositions are heavily-tailed, the consensus location and
dispersion are estimated using robust estimators: the median
for location and the scale-adjusted median absolute deviation
from the median (MADE) for dispersion. The horizontal axis
displays the variability of bias estimates, estimated as the SD.
or “apparent precision” of the biases:
s(zi) j((xij 	 x j)/sj)2/(nj 	 1)
The semicircles mark one, two, and three “comparability”
distances from the ideal (zi, s(zi)) value of (0, 0):
di zi2  s2(zi)
The targetplot dots are color-coded by distance from the
(0, 0) origin: dots within two comparability units are colored
green, between two and three units are colored yellow, and
greater than three units are colored red. These codes roughly
indicate “Good”, “Moderate”, and “Questionable” agreement
with the consensus mod-NISTmAb/NISTmAb ratio estimates.
Fig. 4 displays the same targetplot colored by analyte,
analytical technique, organizational type, and number of rep-
licates. No systematic trend was apparent in any of the
parameters.
Youden Two-Sample Plots of Glycan Compositions—Fig. 5
shows Youden two-sample plots for the four most abundant
glycan compositions, [h3n4f1], [h4n4f1], [h5n4f1] and
[h3n3f1]. Supplemental Fig. S6 presents similar plots for all
compositions with quantitative results for both samples in at
least six data sets. Each dot in these panels represents one
(mod-NISTmAb, NISTmAb) pair from one data set. The me-
dian of each sample is used as the univariate estimate of
distribution location because it is not as vulnerable to extreme
values as is the mean. The center of each panel (for [h3n4f1],
the values (52, 39)) represents the consensus location of the
resulting bivariate distribution. The ellipse in each panel is
constructed to enclose data pairs that are consistent with the
consensus medians at an approximate 68% (one sigma) level
of confidence. These ellipses are defined by (1 the univariate
medians, (2 the MADE robust estimates of the univariate SDs,
(3 the bivariate correlation between the two distributions, and
(4 a factor that provides a stated coverage probability.
FIG. 4. Targetplot summary of mod-NISTmAb/NISTmAb ratios relative to the consensus medians. Each dot represents one set of
results. Dot diameter is proportional to number of ratios reported. The “Average Bias” axis displays values estimated as the mean of the
“Z-scores” of the ratios. The “Bias Variability axis displays values estimated as the standard deviation of the Z-scores. The subplots are colored
by: A) analytical technique, B) analyte, C) laboratory type, and D) number of replicates.
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When the two samples present similar measurement chal-
lenges, Youden two-sample plots graphically separate ran-
dom within-data set measurement imprecision from system-
atic between-data set bias (35, 36). Pairs of measurements
that reflect the same proportional bias will fall along the 45o
line. This often indicates a calibration issue. Pairs of meas-
urements that lie well away from the line indicate sample-
specific interferences or measurement systems that are not in
adequate statistical control.
The dots in Fig. 5 are colored by separation method. Es-
sentially all laboratories that used HILIC separation are within
the ellipse for [h3n4f1] and [h4n4f1], are within the ellipse or lie
along the diagonal for [h3n3f1] but show significant scatter for
[h5n4f1]. The pattern of off-diagonal results for [h5n4f1] sug-
gests that for this composition the two samples presented
several measurement systems with different measurement
challenges.
Measurement Repeatability Better for More Abundant Gly-
cans—Metrological repeatability is defined as the variation in
measurements taken by a single person or instrument on the
same sample, under the same conditions, and in a short
period of time. Fig. 6 shows a scatterplot of the relationship
between measurement repeatability, estimated as the coef-
ficient of variation expressed as percentage (CV), and gly-
can amount, estimated as the mean of the replicates, for
one exemplar laboratory. The black line represents a simple
consensus power-law: CV  5.0  Mean	0.35 (or, ex-
pressed as SD  0.050  Mean0.65). Note that CV is not
constant for all glycan amounts but rather generally in-
creases with decreasing amount. This trend is closely re-
FIG. 5. Youden two-sample plots for the four most abundant glycan compositions in NISTmAb. Each panel displays the bivariate
distribution for one composition. A) [h4n4f1], B) [h3n4f1], C) [h5n4f1], and D) [h3n3f1] (see Materials and Methods for key). The panels are
centered on the univariate medians and scaled to display all values from 0 to twice the median. Values that are greater than twice the median
are assigned a value of twice the median. The ellipse includes about 68% of the pairs (
 1 SD). The diagonal line represents the expected
relationship when measurement systems have the same bias for both samples. Each symbol represents the (mod-NISTmAb, NISTmAb) pair
for one data set. Symbols are coded and labeled by separation technique.
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lated to Horwitz’s observation that the interlaboratory study
CV generally increases with decreasing analyte concentra-
tion regardless of the analytical method or number of labo-
ratories (37). It has been speculated that this empirical trend
arises more from cost-benefit considerations than intrinsic
analytical limitations (38).
Repeatable Measurements are Closer to Community’s Con-
sensus Values—The extent of agreement between a given
laboratory’s reported values and the study’s consensus me-
dian values is a strong function of the laboratory’s measure-
ment repeatability. Thus, establishing within-laboratory re-
peatability is critical to the harmonization of glycosylation
analysis methods between-laboratories. Fig. 7 shows a scat-
terplot of the closeness to consensus of the reported medians
as a function of measurement repeatability. “Closeness” is
estimated as the relative absolute difference between a given
result mean and the median of the means provided in all 103
reports: 100 Mean-Consensus Median /Mean. The symbols
are coded by the user-stated nature of the reported repli-
cates. Because of the great variability in the results for the
various glycans, the over-all repeatability for each laboratory
is estimated as the median of the repeatabilities of the re-
ported unique glycan compositions.
Trueness of the Consensus Estimates—Metrological true-
ness is the closeness of a result to the best available approx-
imation to its (unknowable) true value. Area-based estimates
for 27 resolved NISTmAb peaks of defined composition have
been published (22). Unique correspondences can be es-
tablished between glycan compositions and most of the
peak assignments, Fig. 8 demonstrates that the study’s
consensus medians agree well with published values for
composition levels of 1% or more. While agreement di-
verges with decreasing abundance, only three of the pub-
lished values are not contained within the study’s central
50% distribution.
In broad terms, a large proportion of methods used chro-
matography for separation followed by identification either by
mass spectrometry or chromatographic retention times.
Some laboratories combined both for identification. Labora-
FIG. 7. Scatterplot of the closeness to consensus of the re-
ported values as a function of measurement repeatability esti-
mated as CV. The symbols are coded by the user-stated nature of
the reported replicates. The plot shows the data point, in blue dia-
mond, of one data set.
FIG. 8. Comparison Consensus Medians to Published Peak Ar-
eas22. Each symbol represents this interlaboratory study’s consensus
median % proportion as a function of the published peak areas for
one composition or defined group of compositions. The bars span the
central 50% of the distribution of reported values. The solid red
circles denote compositions where the central 50% of the values
does not include the published peak area. The dashed line represents
equality between the two estimates.
FIG. 6. Scatterplot of the relationship between measurement
repeatability, estimated as the CV, and glycan amount, estimated
as the mean of the replicates. The black line represents a consen-
sus power curve fit to all available (mean of replicates, relative stand-
ard deviation) pairs, denoted by the light gray dots: CV 
5.0  Mean	0.35 (or SD  0.050  Mean0.65). The red line is the
power curve fit to the pairs, denoted by the blue diamonds, reported
in one data set. The measurement repeatability or this data set is
somewhat better than average.
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tories that used MS only reported more distinct glycan com-
positions. Laboratories that used MS with exoglycosidases,
RT, FD, and/or MS/MS reported isomers. However, the range
in the number of reported compositions within each category
is quite large.
CONCLUSION
Community consensus medians for 57 glycan composi-
tions in NISTmAb were obtained from 103 reports of 76 lab-
oratories. Levels of sialylation (NeuAc and NeuGc), galacto-
sylation (including alpha-galactosylation), and fucosylation
(core and antenna) were calculated from consensus medians.
These values could be useful in comparing analytical methods
for determining glycosylation of a publicly-available material.
A unique advantage of using NISTmAb is that because it was
produced in NS0 cells, a rich array of glycan compositions
with low-abundant variants including NeuGc and alpha-Gal-
containing glycans is observed.
More importantly, this study provides an overview of the
current state of glycosylation determination in the glycomics
community:
1. Most biopharmaceutical company laboratories analyzed
glycosylation using fluorescently-labeled glycans whereas
most academic laboratories prefer glycopeptide analysis
and non-fluorescently-labeled glycan analysis. On aver-
age, biopharmaceutical company laboratories reported
lower number of glycan compositions than university lab-
oratories.
2. Glycan compositions identified using different methods
for determining glycosylation ranged from 4 to 48 com-
positions. Laboratories that used glycopeptides as ana-
lyte, on the average, reported the greatest number of
glycan compositions.
3. Agreement to the community’s consensus medians did
not depend on a specific method or laboratory type but
on the measurement repeatability. The better a laborat-
ory’s measurement precision the more likely that the
laboratory’s mean values will agree with the community
consensus. Thus, establishing within-laboratory repeat-
ability is critical to the harmonization of glycosylation
analysis methods between-laboratories.
4. Most methods used in the different laboratories could be
corrected by calibration methods when and if a standard
becomes available.
5. Measurement repeatability was better for more abundant
glycans. The CVs increased with decreasing glycan
abundances. This work is the first attempt to analyze
data from the interlaboratory study. Further data mining
studies on this large data set could be valuable to the
glycomics communty to uncover underlying systematic
trends. Examples of potential studies include compari-
sons of identification methods, quantification methods,
or normalization methods. Other areas to explore include
assigning degrees of confidence in identification meth-
ods (e.g. identification by MS1 alone versus identification
by MS1 with one, two, or three orthogonal values).
The study shows a clear need for harmonization of glyco-
sylation analysis methods. Further understanding of causes of
deviations would be useful in developing a harmonized
method for glycosylation analyses of mAbs.
Finally, we note that the generally unsatisfactory state of
confident identification of less abundant glycan structures.
While the increasing sensitivity of mass spectrometry-based
methods have revealed an increasingly large number of glycan
compositions, the ability to elucidate their structures have not
kept pace. In many cases, glycan structures are routinely in-
ferred through biological reasoning. The use of exoglycosidases
is helpful in excluding candidates, but of limited value for minor
glycans or complex mixtures. Perhaps the emerging field of ion
mobility mass spectrometry can aid the distinction of isomers.
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